ArticleNeuro-oncology practice2021
Durable 5-year local control for resected brain metastases with early adjuvant SRS: the effect of timing on intended-field control.
Article in Neuro-oncology practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 36 citations in OpenAlex.
- Outcomes of hypofractionated stereotactic radiotherapy for brain metastases: do we treat patients or lesions?BMC cancer · 2026Article
- Evaluation of disparities in timely stereotactic radiosurgery for brain metastases in a safety net hospital system through a centralized workflow.Journal of neuro-oncology · 2026Article
- The evolving landscape of brain metastasis: volume II.Trends in cancer · 2026Review
- An Integrated Dataset of Metastatic Breast Cancer to the Brain with Imaging, Radiomics, and Tumor Genetics.Scientific data · 2025Article
- Survival Among Patients With ERBB2-Positive Metastatic Breast Cancer and Central Nervous System Disease.JAMA network open · 2025Article
- Genomic analysis of human brain metastases treated with stereotactic radiosurgery reveals unique signature based on treatment failure.iScience · 2024Article
- Intracranial Outcomes of De Novo Brain Metastases Treated With Osimertinib Alone in Patients With Newly Diagnosed EGFR-Mutant NSCLC.JTO clinical and research reports · 2023Article
- Outcomes Following Early Postoperative Adjuvant Radiosurgery for Brain Metastases.JAMA network open · 2023Article
- Postradiosurgery cystic degeneration in brain metastases causing delayed and potentially severe sequelae: systematic review and illustrative cases.Journal of neurosurgery. Case lessons · 2023Article
- Low-Energy X-Ray Intraoperative Radiation Therapy (Lex-IORT) for Resected Brain Metastases: A Single-Institution Experience.Cancers · 2022Article
- Reply to letter to the editor: Does early adjuvant brain metastasis SRS increase mortality?Neuro-oncology practice · 2022Article
- Does early adjuvant brain metastasis SRS increase mortality?Neuro-oncology practice · 2022Article
- Integrated Multidisciplinary Brain Metastasis Care Reduces Patient Visits and Shortens Time to Adjuvant Irradiation.JCO oncology practice · 2022Article
- Neoadjuvant stereotactic radiosurgery for brain metastases: a new paradigm.Neurosurgical focus · 2022Article
- Patient-specific radiological protection precautions following Cs collagen embedded Cs-131 implantation in the brain.Journal of applied clinical medical physics · 2022Article
- Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan.CNS oncology · 2022Article
- Outcomes and Molecular Features of Brain Metastasis in Gastroesophageal Adenocarcinoma.JAMA network open · 2022Article
- Brachytherapy for central nervous system tumors.Journal of neuro-oncology · 2022Review
- Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG.Journal for immunotherapy of cancer · 2022Article
- Risk of tract recurrence with stereotactic biopsy of brain metastases: an 18-year cancer center experience.Journal of neurosurgery · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
backgroundAdjuvant stereotactic radiosurgery (SRS) improves the local control of resected brain metastases (BrM). However, the dependency of long-term outcomes on SRS timing relative to surgery remains unclear.
methodsRetrospective analysis of patients treated with metastasectomy-plus-adjuvant SRS at Memorial Sloan Kettering Cancer Center (MSK) between 2013 and 2016 was conducted. Kaplan-Meier methodology was used to describe overall survival (OS) and cumulative incidence rates were estimated by type of recurrence, accounting for death as a competing event. Recursive partitioning analysis (RPA) and competing risks regression modeling assessed prognostic variables and associated events of interest.
resultsTwo hundred and eighty-two patients with BrM had a median OS of 1.5 years (95% CI: 1.2-2.1) from adjuvant SRS with median follow-up of 49.8 months for survivors. Local surgical recurrence, other simultaneously SRS-irradiated site recurrence, and distant central nervous system (CNS) progression rates were 14.3% (95% CI: 10.1-18.5), 4.9% (95% CI: 2.3-7.5), and 47.5% (95% CI: 41.4-53.6) at 5 years, respectively. Median time-to-adjuvant SRS (TT-SRS) was 34 days (IQR: 27-39). TT-SRS was significantly associated with surgical site recurrence rate (
conclusionsAdjuvant SRS provides durable local control. However, delays in initiation of postoperative SRS can decrease its efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.